Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Of the 47 men enrolled onto this multicenter cooperative group study, 46 were assessable for response and/or toxicity. In the 24 patients with measurable disease, there were three complete and nine partial responses for a measurable disease response rate of 50% (12 of 24 patients; 95% confidence interval [CI], 27% to 73%). In the 44 patients in whom pretreatment prostate-specific antigen (PSA) was elevated, 30 (68%) had a 50% or greater decrease, and 25 (57%) had a 75% or greater decrease in PSA. The combined measurable disease and biochemical response rate in all 46 assessable patients was 54% (three complete responses, 22 partial responses, 95% CI, 37% to 71%). The predominant toxicity was neutropenia, with 26% of patients having grade 3 and 30% having grade 4 granulocytopenia; there were no episodes of febrile neutropenia. Other common but mild adverse effects included malaise/ fatigue, peripheral edema, and hyperglycemia. The incidence of thromboembolic events during therapy was 9%. With a median follow-up of 17 months, the median survival was 20 months. The median time to disease progression was 8 months for all patients, and 10 months for those with measurable disease. CONCLUSION:
|
Authors | D M Savarese, S Halabi, V Hars, W L Akerley, M E Taplin, P A Godley, A Hussain, E J Small, N J Vogelzang |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 19
Issue 9
Pg. 2509-16
(May 01 2001)
ISSN: 0732-183X [Print] United States |
PMID | 11331330
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Taxoids
- Docetaxel
- Estramustine
- Paclitaxel
- Hydrocortisone
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Docetaxel
- Estramustine
(administration & dosage)
- Humans
- Hydrocortisone
(administration & dosage)
- Male
- Paclitaxel
(administration & dosage, analogs & derivatives)
- Prostatic Neoplasms
(drug therapy, mortality)
- Survival Rate
- Taxoids
|